Novartis Australia responds to pandemic challenges faced by patient organisations
Novartis is responding to the challenges faced by patient organisations with the announcement of three key initiatives to help them continue their critical work throughout the COVID-19 crisis.
Novartis to assist Australian Government with initial supply of hydroxychloroquine
Novartis Australia, and its generics and biosimilars division Sandoz, has confirmed that it will be working with the Australian government to provide an initial supply of generic hydroxychloroquine to support the COVID-19 pandemic response.
Coronavirus (COVID-19) Novartis Australia & New Zealand
Novartis in Australia and New Zealand continues to closely monitor and respond to the coronavirus (COVID-19) situation. Our priority is to ensure the health and safety of our people, patients, and healthcare professionals.